02.06.2013 Views

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

196 DROPERIDOL<br />

Other<br />

Anaphylactoid reactions/Anaphylaxis<br />

(1984): Aguilera Celorrio L+, Rev Esp Anestesiol Reanim<br />

31(6), 249<br />

(1984): Aren Frontera JJ+, Rev Esp Anestesiol Reanim 31(2), 75<br />

(1984): Occelli G+, AnnFrAnesthReanim3(6), 440<br />

Chills<br />

Death<br />

(2004): Cox RD+, Vet Hum Toxicol 46(1), 21 (2 cases)<br />

(2004): Mullins M+, Am J Emerg Med 22(1), 27 (99 cases)<br />

(2001): Glassman AH+, Am J Psychiatry 158(11), 1774<br />

Rhabdomyolysis<br />

(1983): Reis J+, Rev Neurol (Paris) 139(10), 595<br />

DROTRECOGIN ALFA<br />

Trade name: Xigris (Lilly)<br />

Indications: Severe sepsis<br />

Category: Recombinant protein C<br />

Half-life: 1.6 hours<br />

Clinically important, potentially hazardous interactions<br />

with: None<br />

Skin<br />

Purpura (>10%)<br />

DULOXETINE<br />

Reactions<br />

Trade name: Cymbalta (Lilly)<br />

Indications: Depression<br />

Category: Antidepressant; Noradrenaline reuptake inhibitor;<br />

Serotonin reuptake inhibitor<br />

Half-life: 8–17 hours<br />

Clinically important, potentially hazardous interactions<br />

with: cimetidine, ciprofloxacin, enoxacin, fluoxetine,<br />

fluvoxamine, MAO inhibitors, paroxetine, quinidine, thioridazine<br />

Reactions<br />

Skin<br />

Acne (

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!